Latest Innovation News

Challenger Limited has welcomed APRA’s proposed capital standards for longevity products, highlighting their potential to reduce capital requirements and stimulate growth in Australia’s retirement income sector.

1414 Degrees has completed key milestones on its SiBox technology, advanced SiBrick storage media towards mass production, and acquired an exclusive licence for innovative silicon nanoparticle tech, backed by a $1.214 million capital raise.

BlinkLab has completed its U.S. autism pilot study with strong diagnostic accuracy and expanded its pivotal FDA trial to seven leading research centers, positioning itself for regulatory submission in late 2026.

Stakk Limited has landed a significant contract with leading U.S. neobank Chime, integrating its embedded finance technology to support millions of users and targeting $8 million in annual recurring revenue by year-end.

Zimi Limited reported a remarkable 367% increase in quarterly revenue alongside a successful $1.85 million capital raise and completion of its manufacturing relocation, setting the stage for accelerated growth in the smart home IoT sector.

Data # 3 Limited showcased strong FY25 financial results with record $3 billion gross sales and announced key board changes at its 2025 AGM. The company projects steady growth for FY26 despite some short-term challenges.

Ionic Rare Earths advances its global rare earths strategy with significant UK government funding, increased heavy rare earth oxide production, and a $15.6 million capital raise backed by a strategic US investor.

L1 Group has completed its merger with Platinum Asset Management, forming a $16.9 billion investment powerhouse focused on stabilising funds under management and unlocking significant cost synergies.

Locate Technologies reports a 19% revenue increase in its Locate2u segment and progresses toward a December 2025 NZX listing, supported by new board appointments and a NZD 10 million ATM facility.

Archer Materials has successfully demonstrated that its blood potassium Biochip can be fabricated on a silicon platform, matching clinical accuracy standards and accelerating its path to commercialisation.

Doctor Care Anywhere reports a 7.5% rise in consultations excluding secondary care and sustains positive cashflow for the second consecutive quarter, reaffirming ambitious medium-term growth targets.

Rhythm Biosciences reports strong Q1 FY26 progress, securing strategic partnerships and advancing commercial readiness for its ColoSTAT® colorectal cancer test alongside robust growth in its geneType platform.